Charles River Laboratories Joins Exostar’s Life Sciences Community
News Feb 28, 2014
Exostar has recognized Charles River Laboratories as the first clinical research organization (CRO) to join Exostar’s rapidly growing Life Sciences community, which currently includes numerous CROs among the more than 500 organizations and 10,000 individuals in almost 50 countries worldwide.
The Exostar Life Sciences Identity Hub brings CROs, pharmaceutical manufacturers, academic institutions, and others in the industry together in an environment that facilitates secure collaboration, reduces capital and operating expenditures, and drives revenue by enhancing productivity and speeding time-to-market.
Charles River provides essential products and services including basic research, discovery, safety and efficacy, clinical support, and process manufacturing. Leading pharmaceutical and biotechnology companies, government agencies, and academic institutions around the world count on Charles River to accelerate their research and drug development efforts.
Organizations need only connect once to the cloud-based Exostar Life Sciences Identity Hub, opening the door to external partner collaboration through portals, applications, and information sharing.
Because the Exostar solution is delivered as-a-Service, organization and user provisioning can be standardized and streamlined, slashing the time to collaboration from weeks or months to days.
Exostar controls access to the community and its assets through its Secure Access Manager (SAM) service offering. SAM verifies identities of individuals and permits access based on authentication methods and permissions defined by asset owners.
Charles River opted for SAM’s Enterprise Access Gateway (EAG) capability to more closely integrate with the community. With EAG, Charles River employees benefit from a true single sign-on experience, using their existing credentials to reach partner assets.
“Charles River’s commitment to being a fully integrated partner with its customers makes our Life Sciences collaboration platform a perfect complement to its mission,” said Vijay Takanti, Exostar’s Vice President of Security and Collaboration Solutions. “Other CROs and industry partners are enhancing their value by following Charles River’s lead and becoming part of our community.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE